Nuo Therapeutics, Inc. announced that it has entered into a securities purchase agreement for private placement of 3,550,000 common shares at a price of $1 per share for proceeds of $3,550,000 on April 11, 2022. The transaction will include participation from David E. Jorden, the Chief Executive and Financial Officer of the company, Scott M. Pittman, directors of the company, Peter A. Clausen, the Chief Scientific Officer and Chief Operating Officer of the company, and Charles E. Sheedy, a principal stockholder of the company, Messrs. Jorden, Pittman, Clausen, and Sheedy invested $10,532, $100,000, $25,000, and $804,868, respectively in the transaction.

The transaction is expected to close on April 29, 2022 but will put reasonable best efforts to close not later than April 25, 2022. The securities are issued pursuant to Section 4(a)(2) of the Securities Act of 1933, and Rule 506 of Regulation D.